Dataset Information

Revealing protein networks and gene-drug connectivity in cancer from direct information.

ABSTRACT: The connection between genetic variation and drug response has long been explored to facilitate the optimization and personalization of cancer therapy. Crucial to the identification of drug response related genetic features is the ability to separate indirect correlations from direct correlations across abundant datasets with large number of variables. Here we analyzed proteomic and pharmacogenomic data in cancer tissues and cell lines using a global statistical model connecting protein pairs, genes and anti-cancer drugs. We estimated this model using direct coupling analysis (DCA), a powerful statistical inference method that has been successfully applied to protein sequence data to extract evolutionary signals that provide insights on protein structure, folding and interactions. We used Direct Information (DI) as a metric of connectivity between proteins as well as gene-drug pairs. We were able to infer important interactions observed in cancer-related pathways from proteomic data and predict potential connectivities in cancer networks. We also identified known and potential connections for anti-cancer drugs and gene mutations using DI in pharmacogenomic data. Our findings suggest that gene-drug connections predicted with direct couplings can be used as a reliable guide to cancer therapy and expand our understanding of the effects of gene alterations on drug efficacies.

SUBMITTER: Jiang XL

PROVIDER: S-EPMC5473890 | biostudies-other | 2017 Jun

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Revealing protein networks and gene-drug connectivity in cancer from direct information.

Jiang Xian-Li XL Martinez-Ledesma Emmanuel E Morcos Faruck F

Scientific reports 20170616 1

The connection between genetic variation and drug response has long been explored to facilitate the optimization and personalization of cancer therapy. Crucial to the identification of drug response related genetic features is the ability to separate indirect correlations from direct correlations across abundant datasets with large number of variables. Here we analyzed proteomic and pharmacogenomic data in cancer tissues and cell lines using a global statistical model connecting protein pairs, g ...[more]

PMID: 28623316

Similar Datasets

Project description:Carcinogenesis is a complex process with multiple genetic and environmental factors contributing to the development of one or more tumors. Understanding the underlying mechanism of this process and identifying related markers to assess the outcome of this process would lead to more directed treatment and thus significantly reduce the mortality rate of cancers. Recently, molecular diagnostics and prognostics based on the identification of patterns within gene expression profiles in the context of protein interaction networks were reported. However, the predictive performances of these approaches were limited. In this study we propose a novel integrated approach, named CAERUS, for the identification of gene signatures to predict cancer outcomes based on the domain interaction network in human proteome. We first developed a model to score each protein by quantifying the domain connections to its interacting partners and the somatic mutations present in the domain. We then defined proteins as gene signatures if their scores were above a preset threshold. Next, for each gene signature, we quantified the correlation of the expression levels between this gene signature and its neighboring proteins. The results of the quantification in each patient were then used to predict cancer outcome by a modified naïve Bayes classifier. In this study we achieved a favorable accuracy of 88.3%, sensitivity of 87.2%, and specificity of 88.9% on a set of well-documented gene expression profiles of 253 consecutive breast cancer patients with different outcomes. We also compiled a list of cancer-associated gene signatures and domains, which provided testable hypotheses for further experimental investigation. Our approach proved successful on different independent breast cancer data sets as well as an ovarian cancer data set. This study constitutes the first predictive method to classify cancer outcomes based on the relationship between the domain organization and protein network.

Project description:The recently proposed concept of molecular connectivity maps enables researchers to integrate experimental measurements of genes, proteins, metabolites, and drug compounds under similar biological conditions. The study of these maps provides opportunities for future toxicogenomics and drug discovery applications. We developed a computational framework to build disease-specific drug-protein connectivity maps. We integrated gene/protein and drug connectivity information based on protein interaction networks and literature mining, without requiring gene expression profile information derived from drug perturbation experiments on disease samples. We described the development and application of this computational framework using Alzheimer's Disease (AD) as a primary example in three steps. First, molecular interaction networks were incorporated to reduce bias and improve relevance of AD seed proteins. Second, PubMed abstracts were used to retrieve enriched drug terms that are indirectly associated with AD through molecular mechanistic studies. Third and lastly, a comprehensive AD connectivity map was created by relating enriched drugs and related proteins in literature. We showed that this molecular connectivity map development approach outperformed both curated drug target databases and conventional information retrieval systems. Our initial explorations of the AD connectivity map yielded a new hypothesis that diltiazem and quinidine may be investigated as candidate drugs for AD treatment. Molecular connectivity maps derived computationally can help study molecular signature differences between different classes of drugs in specific disease contexts. To achieve overall good data coverage and quality, a series of statistical methods have been developed to overcome high levels of data noise in biological networks and literature mining results. Further development of computational molecular connectivity maps to cover major disease areas will likely set up a new model for drug development, in which therapeutic/toxicological profiles of candidate drugs can be checked computationally before costly clinical trials begin.

Project description:Estimation of functional connectivity (FC) has become an increasingly powerful tool for investigating healthy and abnormal brain function. Static connectivity, in particular, has played a large part in guiding conclusions from the majority of resting-state functional MRI studies. However, accumulating evidence points to the presence of temporal fluctuations in FC, leading to increasing interest in estimating FC as a dynamic quantity. One central issue that has arisen in this new view of connectivity is the dramatic increase in complexity caused by dynamic functional connectivity (dFC) estimation. To computationally handle this increased complexity, a limited set of dFC properties, primarily the mean and variance, have generally been considered. Additionally, it remains unclear how to integrate the increased information from dFC into pattern recognition techniques for subject-level prediction. In this study, we propose an approach to address these two issues based on a large number of previously unexplored temporal and spectral features of dynamic functional connectivity. A Generalized Autoregressive Conditional Heteroskedasticity (GARCH) model is used to estimate time-varying patterns of functional connectivity between resting-state networks. Time-frequency analysis is then performed on dFC estimates, and a large number of previously unexplored temporal and spectral features drawn from signal processing literature are extracted for dFC estimates. We apply the investigated features to two neurologic populations of interest, healthy controls and patients with temporal lobe epilepsy, and show that the proposed approach leads to substantial increases in predictive performance compared to both traditional estimates of static connectivity as well as current approaches to dFC. Variable importance is assessed and shows that there are several quantities that can be extracted from dFC signal which are more informative than the traditional mean or variance of dFC. This work illuminates many previously unexplored facets of the dynamic properties of functional connectivity between resting-state networks, and provides a platform for dynamic functional connectivity analysis that facilitates its usage as an investigative measure for healthy as well as abnormal brain function.

Project description:Cellular communication strongly relies on the secretion of soluble mediators that, in general, interact with cell surface receptors and enable biological responses in a proper timescale for signaling processes to occur. Therefore, the study of secreted proteins (the secretome) from normal cells and tumoral counterparts allows a comprehensive portrait of the so-called ‘effectors’ in many biological circuits, including those related to tumor development. Cell homeostasis is disrupted in many ways during oncogenesis; the main biological implications are derived from a wide range of factors, including somatic mutations, epigenetic modifications and post-transcriptional/translational modifications, which ultimately results in the modulation of the gene expression. Collectively, these factors often result in rewiring connections in signaling networks in malignant cells. Since protein-protein interactions may eventually enable transformed cells to grow, proliferate and invade neighboring tissues, a comprehensive view of the imbalance caused by the oncogenic processes requires the understanding of the interplay of interactors in altered biological circuits. Pathway and network analysis are analytic approaches that reduce the data involving thousands of altered genes/proteins in complex biological systems to smaller datasets which, in turn, enable the detection and interpretation of specific biological questions such as cancer-related processes, clinically distinct outcomes and drug targets, for example. In this respect, protein-protein interaction networks (PPINs) are static representations of protein connections in biological systems. Although this simplification lacks the dynamic nature of the real protein world, it allows the identification of specific topologies related to the patterns of connectivity of a given PPIN. Moreover, some additional network features may be observed, such as the identification of subgraphs (communities), which contain proteins that may be functionally related, revealing an additional layer of complexity among protein-protein interactions within the network. Kaushik and coworkers used network analysis and to study melanoma stage progression and found that melanoma-related genes can modulate their activities by rewiring network connections, independent of altered gene expression. A recent work with DNA methylation, gene expression and corresponding clinical data from breast invasive carcinoma, skin cutaneous melanoma and uterine corpus endometrial carcinoma underscored gene co-methylation networks, resulting in the identification of core gene modules which allowed the molecular typing of cancer and the prognosis of patients. Such network-based approach revealed that gene modules were more reliable in cancer prognosis than gene expression profiles. Systems-level analysis of signaling networks, gene expression profiles and cell phenotyping, in combination with mathematical modeling, helped to understand the interface between growth factor and DNA signaling pathways in breast cancer9. According to the authors, the identification of rewiring patterns in apoptotic signaling pathways may have main implications for combined therapies in the treatment of breast cancer. In this context, the main goal of this work was to profile the secretome composition of a murine cellular melanoma model composed by a normal melanocyte cell line, Melan-a, and its tumoral phenotype, Tm1, using the proteomic data to build interactomes for both secretomes. Our data revealed an expressive rewiring in the tumoral interactome of secreted proteins, with important biological roles in malignant transformation including the transforming growth factor beta (TGF-beta) signaling pathway.

Dataset Information

Revealing protein networks and gene-drug connectivity in cancer from direct information.

Publications

Revealing protein networks and gene-drug connectivity in cancer from direct information.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets